Free Trial
Andrew Tsai

Andrew Tsai Analyst Performance

Senior Vice President at Jefferies Financial Group

Andrew Tsai is a stock analyst at Jefferies Financial Group focused in the medical sector, covering 13 publicly traded companies. Over the past year, Andrew Tsai has issued 11 stock ratings, including buy and hold recommendations. While full access to Andrew Tsai's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew Tsai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 5 Years
Buy Recommendations
76.92% 10 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy76.9%10 ratings
Hold23.1%3 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Andrew Tsai at Jefferies Financial Group, the majority (76.9%) have been Buy recommendations, followed by 23.1% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.3% of companies on NASDAQ
12 companies
NYSE
7.7% of companies on NYSE
1 company

Andrew Tsai, an analyst at Jefferies Financial Group, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
92.3%
Computer and Technology
1 company
7.7%

Andrew Tsai of Jefferies Financial Group specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
61.5%
MED - GENERIC DRG
1 company
7.7%
MED - OUTP/HM CRE
1 company
7.7%
INTERNET SERVICES
1 company
7.7%
PHARMACEUTICAL PREPARATIONS
1 company
7.7%
MED - DRUGS
1 company
7.7%

Andrew Tsai's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
10/9/2025Downgrade$54.19$56.00Hold
Biogen Inc. stock logo
BIIB
Biogen
9/25/2025Initiated Coverage$137.67$190.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/24/2025Lower Price Target$10.92$35.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
7/18/2025Initiated Coverage$12.35$30.00Buy
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/14/2025Initiated Coverage$46.47$70.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/16/2025Lower Price Target$20.65$54.00Buy
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
6/11/2025Boost Price Target$90.82$110.00Buy
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/28/2025Reiterated Rating$2.33Hold
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
5/20/2025Set Price Target$2.02$5.00
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4/7/2025Initiated Coverage$98.86$200.00Buy
KE Holdings Inc. Sponsored ADR stock logo
BEKE
KE
3/19/2025Boost Price Target$22.22$27.00Overweight